FCPR03

目录号: PL09168 纯度: ≥99%
FCPR03 是一种有效的选择性的磷酸二酯酶 4 (PDE4) 抑制剂,对于 PDE4 催化域,PDE4B1 和 PDE4D7,IC50 值分别为 60 nM,31 nM 和 47 nM。FCPR03 对 PDE4 的选择性比其他 PDE (PDE1-3 和 PDE5-11) 至少高 2100 倍。FCPR03 具有抗炎,神经保护和抗抑郁样作用。
CAS No. :1917347-65-9
商品编号 规格 价格 会员价 是否有货 数量
PL09168-5mg 5mg ¥828.00 请登录
PL09168-10mg 10mg ¥1345.00 请登录
PL09168-25mg 25mg ¥2185.00 请登录
PL09168-50mg 50mg ¥2975.00 请登录
PL09168-100mg 100mg ¥4025.00 请登录
PL09168-200mg 200mg ¥5425.00 请登录
PL09168-1 mL x 10 mM (in DMSO) 1 mL x 10 mM (in DMSO) ¥905.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
*注意事项:下单时请联系销售核实产品价格及货期,避免后续产生不便,感谢支持!
中文名称
FCPR03
英文名称
FCPR03
英文别名
FCPR03
Cas No.
1917347-65-9
分子式
C15H19F2NO3
分子量
299.31
包装储存
Powder -20°C 3 years;4°C 2 years
详情描述

FCPR03 是一种有效的选择性的磷酸二酯酶 4 (PDE4) 抑制剂,对于 PDE4 催化域,PDE4B1 和 PDE4D7,IC50 值分别为 60 nM,31 nM 和 47 nM。FCPR03 对 PDE4 的选择性比其他 PDE (PDE1-3 和 PDE5-11) 至少高 2100 倍。FCPR03 具有抗炎,神经保护和抗抑郁样作用。

产品详情
FCPR03 是一种有效的选择性的磷酸二酯酶 4 (PDE4) 抑制剂,对于 PDE4 催化域,PDE4B1 和 PDE4D7,IC50 值分别为 60 nM,31 nM 和 47 nM。FCPR03 对 PDE4 的选择性比其他 PDE (PDE1-3 和 PDE5-11) 至少高 2100 倍。FCPR03 具有抗炎,神经保护和抗抑郁样作用。
生物活性
FCPR03 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC 50 values of 60 nM, 31 nM and 47 nM for PDE4 catalytic domain, PDE4B1 and PDE4D7, respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11). FCPR03 has anti-inflammatory, neuroprotective and antidepressant-like effects.
性状
Solid
IC50 & Target[1][2]
PDE4 catalytic domain 60 nM (IC50) PDE4B1
体外研究(In Vitro)
FCPR03 (5-20 μM; 30 hours; HT-22 cells) treatment increases cell viability (oxygen-glucose deprivation (OGD)-induced) in a dose-dependent manner, and 10 μM FCPR03 shows significant protective effects.
FCPR03 (20 μM; 30 hours; HT-22 cells) treatment protects against OGD-induced cellular apoptosis in both HT-22 cells and cortical neurons. The levels of mitochondrial membrane potential (MMP) and ROS are also restored by FCPR03.
FCPR03 (20 μM; 30 hours; HT-22 cells) treatment increases the levels of phosphorylated AKT, glycogen synthase kinase-3β (GSK3β), and β-catenin.
has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
FCPR03 (1.25-5 mg/kg; intraperitoneal injection; once; adult male Sprague-Dawley rats) treatment reduces the infarct volume and improves neurobehavioral outcomes in rats following MCAO. FCPR03 increases the levels of phosphorylated AKT, GSK3β and β-catenin within the ischemic penumbra of rats following cerebral ischemia-reperfusion. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Bingtian Xu, et al. FCPR03, a Novel Phosphodiesterase 4 Inhibitor, Alleviates Cerebral ischemia/reperfusion Injury Through Activation of the AKT/GSK3β/ β-catenin Signaling Pathway. Biochem Pharmacol. 2019 May;163:234-249.
[2]. Zheng-Qiang Zou, et al. Novel Phosphodiesterase 4 Inhibitor FCPR03 Alleviates Lipopolysaccharide-Induced Neuroinflammation by Regulation of the cAMP/PKA/CREB Signaling Pathway and NF- κ B Inhibition. J Pharmacol Exp Ther. 2017 Jul;362(1):67-77.
溶解度数据
In Vitro: DMSO : 100 mg/mL (334.10 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)
[1]. Bingtian Xu, et al. FCPR03, a Novel Phosphodiesterase 4 Inhibitor, Alleviates Cerebral ischemia/reperfusion Injury Through Activation of the AKT/GSK3β/ β-catenin Signaling Pathway. Biochem Pharmacol. 2019 May;163:234-249.
[2]. Zheng-Qiang Zou, et al. Novel Phosphodiesterase 4 Inhibitor FCPR03 Alleviates Lipopolysaccharide-Induced Neuroinflammation by Regulation of the cAMP/PKA/CREB Signaling Pathway and NF- κ B Inhibition. J Pharmacol Exp Ther. 2017 Jul;362(1):67-77.

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2